Reduction in Symptoms After Laser Therapy With Acorn aHFS

A Prospective, Single-blind, Randomized, Placebo-controlled, Clinical Trial Evaluating Reduction in Severity and Duration of Symptoms After Laser Therapy With Acorn aHFS

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06336135

Enrollment

Registered

2024-03-28

Start date

2024-03-25

Completion date

2025-12-02

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Aging

Keywords

skin, aging, rejuvenation, laser resurfacing, autologous secretome

Brief summary

This study evaluates the severity and duration of symptoms experienced after laser therapy comparing four post-procedure topical products. Each product is applied to an individual region of interest (5 cm diameter) on the back or décolleté according to randomization code after laser therapy. The subject, blind to the product applied to each of 4 regions of interest, assesses eight symptoms daily for 14 days. Photography is performed daily.

Interventions

OTHERautologous hair follicle derived secretome

aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or Female * Age: ≥18 and ≤60 years * Any skin tone Fitzpatrick score 1-2 (light), 3-4 (medium), 5-6 (dark) * Competent and willing to provide written, informed consent to participate in all study activities

Exclusion criteria

* Pregnant women * Are participating/have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by Sponsor * Use of retinoids 7 days prior to the procedure * Active cutaneous infections in the treatment area * Diseases that could inhibit healing, such as scleroderma, or other cutaneous conditions that could confound study results * Subjects unable to communicate with the investigator and staff * Any health condition that in the investigator's opinion should preclude participation in this study

Design outcomes

Primary

Measure	Time frame	Description
Reduction in severity and duration of symptoms	2 weeks	Each region of interest will be evaluated daily for the severity and duration of eight symptoms

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026